scPharmaceuticalsNASDAQ: SCPH

The mean of analysts' price targets for scPharmaceuticals (SCPH) points to a 291.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants PJ Kelleher - IR John Tucker - CEO Steve Parsons - SVP, Commercial Rachael Nokes - CFO Conference Call Participants Roanna Ruiz - Leerink Partners Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to the scPharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode.

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.44 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.36 per share a year ago.

BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a public offering price of $4.00 per share and, to select investors, in lieu of common stock, pre-funded warrants to purchase up to 500,000 shares of common stock at a purchase price of $3.999 per underlying share, for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses and excluding the exercise of the pre-funded warrants. The pre-funded warrants have an exercise price of $0.001 per share.  All of the shares and the pre-funded warrants are being offered by scPharmaceuticals. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock from the Company at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on August 13, 2024, subject to the satisfaction of customary closing conditions.

scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million

FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class

SCP-111 Autoinjector achieved primary pharmacokinetic and secondary pharmacodynamic endpoints The autoinjector is being developed to deliver a subcutaneous injection of furosemide as an alternative option to the FDA approved FUROSCIX on-body infusor presentation Company targeting Supplemental New Drug Application (sNDA) submission to the FDA by year-end 2024 BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced positive topline results from the pharmacokinetic (PK) study of SCP-111, an investigational, low volume, pH neutral formulation of furosemide administered via an autoinjector as an alternative to the current on-body infusor used with FUROSCIX.

BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a proposed underwritten public offering of shares (“Shares”) of its common stock or, in lieu of Shares, pre-funded warrants (the “Pre-Funded Warrants”) to purchase Shares (the “Offering”). scPharmaceuticals also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of Shares offered in the Offering. All Shares and Pre-Funded Warrants to be sold in the Offering will be offered by scPharmaceuticals. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering.

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET with Company Representatives PJ Kelleher - Investor Relations, John Tucker - CEO, Steve Parsons - Senior Vice President of Commercial, and Rachael Nokes - CFO. Conference Call Participants include Glen Santangelo from Jefferies, Stacy Ku from TD Cowen, Roanna Ruiz from Leerink Partners, Chase Knickerbocker from Craig-Hallum Capital, Naz Rahman from Maxim Group, and Douglas Tsao from HC Wainwright. The operator begins the call with a welcome message and instructions for participants.